Artículos de revistas
Suramin Attenuates Dystrophin-deficient Cardiomyopathy In The Mdx Mouse Model Of Duchenne Muscular Dystrophy
Registro en:
Muscle And Nerve. , v. , n. , p. - , 2013.
0148639X
10.1002/mus.23858
2-s2.0-84883733538
Autor
Moreira D.D.O.
Pereira J.A.
Taniguti A.P.T.
Matsumura C.Y.
Ramos L.A.F.
Areas M.A.
Neto H.S.
Marques M.J.
Institución
Resumen
Introduction: The purpose of this study was to determine the effects of suramin, an antifibrotic agent, on cardiac function and remodeling in mdx mice. Methods: mdx mice (8 months old) received intraperitoneal injections of suramin twice a week for 3 months. Control mdx mice (8 months old) were injected with saline. Results: Suramin improved the electrocardiography profile with the main corrections seen in S- to R-wave ratio, PR interval, and Q amplitude, and a significant decrease in the cardiomyopathy index. Suramin decreased myocardial fibrosis, inflammation, and myonecrosis. Conclusions: These findings suggest that suramin may be a new adjunctive therapy to help improve cardiomyopathy in DMD. © 2013 Wiley Periodicals, Inc.